Side effects
However, let your doctor know if they continue or get worse. It should not be administered to infants younger than one year old. Before using this medication, pregnant women and nursing mothers should consult their doctors. Temporary and typically transient, these side effects disappear over time. Applying the medication may result in redness, swelling, irritation, itching, or a burning sensation.
Interactions
Patients with a known allergy to fluticasone, any other corticosteroids, or any other inactive ingredients present with this medication shouldn't use it.
Contraindications
Depending on the patient's clinical condition, appropriate corrective actions, dose adjustments, or replacement with a suitable alternative may be necessary. Long-term systemic users of this medication should be checked for candida infection and any other indications of side effects on the nasal and oral mucosa. Depending on the clinical condition, replacement with an appropriate alternative might be required in some circumstances. Report any such symptoms to the doctor immediately. To lessen the likelihood of such side effects, the dose should be increased until it reaches the lowest effective dose. Since this medication may delay healing and make the patient's condition worse, it is not advised to use the nasal spray form of this medication in patients who have recently had nasal trauma, nasal septal ulcers, nasal surgery, etc. until full healing has taken place. Children who take this medication should therefore have their growth metrics closely watched. Some patients may experience other visual disturbances or blurred vision as a result of this medication. Some children who take this medication may experience growth retardation. For some patients, this medication may result in bleeding from the nose and nasal ulcers.
The clinical signs and symptoms of atopic dermatitis were scored on a scale of 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. Two of these trials demonstrated that patients treated with fluticasone propionate nasal spray at a dose of 100 mug twice daily exhibited statistically significant decreases in total nasal symptom scores compared with patients treated with vehicle. Because this trial also used predetermined criteria for lack of efficacy, which caused more patients in the placebo group to be withdrawn, pulmonary function results at Endpoint are included. The mean growth velocities at 52 weeks observed in the intent-to-treat population were 6.32 cm/year in the placebo group (n = 76), 6.07 cm/year in the 50-mug group (n = 98), and 5.66 cm/year in the 100-mug group (n = 89). Fluticasone propionate cream was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range 35-95%).
In these efficacy trials, at all doses, measures of pulmonary function (forced expiratory volume in 1 second [FEV] and morning peak expiratory flow rate [AM PEFR]) were statistically significantly improved as compared with placebo. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma.
Patients should use fluticasone propionate nasal spray at regular intervals as directed since its effectiveness depends on its regular use. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms. • Respiratory : Upper respiratory infection (31% and 19%); influenza (0% and 13%).
TABLE 2 includes all events (whether considered drug-related or nondrug-related by the investigator) that occurred at a rate of over 3% in the combined fluticasone propionate inhalation aerosol groups and were more common than in the placebo group. If chickenpox develops, treatment with antiviral agents may be considered. These adverse reactions were mostly mild to moderate in severity, with 2% of patients discontinuing the studies because of adverse events. Ear, Nose, and Throat: Aphonia, cough, hoarseness, laryngitis, and throat soreness and irritation.
After intranasal treatment of patients with allergic rhinitis for 3 weeks, fluticasone propionate plasma concentrations were above the level of detection (50 pg/ml) only when recommended doses were exceeded and then only in occasional samples at low plasma levels. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens. Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.